The Dicenas drug company has had a tough few months with a number of drugs going into the market that were not as anticipated.
As part of its ongoing turnaround, Dicertas is also working to get rid of some older, non-essential products that are no longer necessary.
Dicerca Pharmaceuticals has been doing the same for some of its older products and the stock is currently up about 11% after a brief period of low volume.
While the stock has been trending lower since its recent upswing, it is still a good value for investors who are concerned about a future drug shortage.
In 2018, the company is expected to post a $5.8 billion net loss, according to a recent Reuters report.
The company also announced that it is selling off some of the remaining Dicetis patents to fund a $2.5 billion acquisition of Nexen Pharmaceuticals.
A quick look at the numbers: Dicernanas is a generic drug that has been around since the 1980s.
It is a common form of blood pressure medication that works by reducing blood pressure in patients with hypertension, diabetes and heart disease.
Its price has been fairly consistent since its launch.
Dicerol is a newer version of Dicerenas drug, which is now a generic.
Its price is currently under $2 per tablet, but is expected go up in the coming years.
Ceftaxin is a new, cheaper version of Ceftazidime, which was introduced in 2019.
Its generic price is expected come in at under $1 per tablet.
The company is also expected to announce that it has signed a deal with Valeant Pharmaceuticals to acquire Nexen’s remaining patents in 2018.
Nexen is a drug that treats hypertension and type 2 diabetes, which can lead to kidney and liver damage.
It is currently in development and is expected take off within the next few years.
Dicercas has been the leader in the market for generic medicines for decades, and this year it is going through a rapid turnaround as it gets rid of older products that have not been tested.
Dicertans company was one of the first to offer its own drug to the market in 2018, and the company continues to be one of its largest shareholders.
This is not the first time that Dicens has gone through a drug shortage that could result in a lower price for its drug.
In October 2018, a generic version of its drug, Dicerol, was recalled due to the lack of efficacy.
The recall led to the company being hit with a $4 billion fine.
At the time, DICerca reported that it had been receiving about 30,000 orders per day for its brand-name product.
This number dropped to about 5,000 per day as of February 2019.
According to data from Merriam-Webster, Dicellin has also seen its generic price drop about 20% from about $3.50 per tablet in 2019 to around $1.50 in 2020.